insights_auto
Why is LYEL down 5.07%?
Dive Deeperchevron_right
LYEL:NASDAQ
Lyell Immunopharma Inc
$8.61
arrow_downward
-5.07%(-0.46) 1D
$8.61
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 6, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LYEL...
Open
$9.13
High
$9.13
Low
$8.58
Mkt. cap
215.41M
Avg. vol.
124.82K
Volume
0.00
52-wk high
$45.00
52-wk low
$8.58
EPS
-$12.01
Beta
-0.03
Shares outstanding
24.50M
No. of employees
161
Open
$9.13
High
$9.13
Low
$8.58
Mkt. cap
215.41M
Avg. vol.
124.82K
Volume
0.00
52-wk high
$45.00
52-wk low
$8.58
EPS
-$12.01
Beta
-0.03
Shares outstanding
24.50M
No. of employees
161
News stories
From web sources and news partners
AD HOC NEWS
·
1 day ago
Lyell completes LYL273 transfer as analysts rate Lyell stock Moderate Buy
Profile
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell, using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors. Wikipedia
About Lyell Immunopharma Inc
CEO-
Employees161
Founded2018
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitelyell.com